GW Pharmaceuticals Jumps As DEA Moves Cannabis-Derived Drug To Low Risk Category

Shares of GW Pharmaceuticals jumped in late morning trading after the company said Epidiolex will be now classified as a Schedule V controlled substance, the lowest ranked class, instead of a Schedule I drug.